{
    "filename": "ea.pl.pdf",
    "content_type": "application/pdf",
    "file_size": 1647464,
    "metadata": {
        "identifiers": {
            "doi": "10.13070/mm.en.10.2867",
            "url": "https://www.labome.com/bin/ea.pl?link=https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf"
        },
        "title": "Wuhan 2019 Novel Coronavirus - 2019-nCoV",
        "author": "Mary Johnson",
        "date": 2020,
        "affiliations": [
            "Additional advice by Malik Peiris, University of Hong Kong",
            "National Institute for Viral Disease Control and Prevention, China, Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, China, and Wuhan Jinyintan Hospital Wuhan Institute of Virology, Chinese Academy of Sciences, China). We acknowledge Professor Yong-Zhen Zhang, Shanghai Public Health Clinical Center & School of Public Health, Fudan University, Shanghai, China for release of another sequence (MN908947)."
        ],
        "journal": "Materials and Methods",
        "volume": "10",
        "references": "@article{corman2012a,\n  author = {Corman, V.M. and Eckerle, I. and Bleicker, T. and Zaki, A. and Landt, O. and Eschbach-Bludau, M.},\n  title = {Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction},\n  journal = {Euro Surveill},\n  date = {2012},\n  volume = {17},\n  more-authors = {true},\n  number = {39},\n  language = {}\n}\n@article{drosten2003a,\n  author = {Drosten, C. and Gunther, S. and Preiser, W. and van der Werf, S. and Brodt, H.R. and Becker, S.},\n  title = {Identification of a novel coronavirus in patients with severe acute respiratory syndrome},\n  journal = {N Engl J Med},\n  date = {2003},\n  volume = {348},\n  pages = {1967\u201376},\n  more-authors = {true},\n  number = {20},\n  language = {}\n}\n@article{drexler2010a,\n  author = {Drexler, J.F. and Gloza-Rausch, F. and Glende, J. and Corman, V.M. and Muth, D. and Goettsche, M.},\n  title = {Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences},\n  journal = {J Virol},\n  date = {2010},\n  volume = {84},\n  pages = {11336\u201349},\n  more-authors = {true},\n  number = {21},\n  language = {}\n}\n@article{muth2018a,\n  author = {},\n  title = {Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission},\n  journal = {Sci Rep},\n  date = {2018},\n  volume = {8},\n  pages = {15177},\n  more-authors = {true},\n  source = {Annex: Annex figure. Non-redundant alignments of SARS-related CoVs focused on oligonucleotide binding sites of all assays (top to bottom: RdRp, E, N). Viruses not present in these alignments have been removed because their binding sites are 100% identical to one of the members of the alignment. (\u201c--\u201c) means sequence gaps not covered by oligonucleotides. Note that these alignments contain only one sequence of 2019-nCoV while Figure 2 above contains all presently released sequences. We will fuse this into one figure},\n  number = {1},\n  language = {}\n}\n@misc{unknown-a,\n  title = {First line screening assay},\n  language = {}\n}\n@misc{unknown-b,\n  title = {Confirmatory assay},\n  language = {}\n}\n@misc{unknown-c,\n  title = {Discrimatory assay},\n  language = {}\n}\n",
        "links": [
            "https://www.european-virus-archive.com/",
            "https://virologie-ccm.charite.de/en/",
            "http://www.gisaid.org"
        ],
        "emails": [
            "christian.drosten@charite.de"
        ],
        "references_ris": "TY  - JOUR\nAU  - Corman, V.M.\nAU  - Eckerle, I.\nAU  - Bleicker, T.\nAU  - Zaki, A.\nAU  - Landt, O.\nAU  - Eschbach-Bludau, M.\nTI  - Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction\nT2  - Euro Surveill\nPY  - 2012\nDA  - 2012\nVL  - 17\nC1  - true\nIS  - 39\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Drosten, C.\nAU  - Gunther, S.\nAU  - Preiser, W.\nAU  - van der Werf, S.\nAU  - Brodt, H.R.\nAU  - Becker, S.\nTI  - Identification of a novel coronavirus in patients with severe acute respiratory syndrome\nT2  - N Engl J Med\nPY  - 2003\nDA  - 2003\nVL  - 348\nSP  - 1967\nEP  - 76\nC1  - true\nIS  - 20\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Drexler, J.F.\nAU  - Gloza-Rausch, F.\nAU  - Glende, J.\nAU  - Corman, V.M.\nAU  - Muth, D.\nAU  - Goettsche, M.\nTI  - Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences\nT2  - J Virol\nPY  - 2010\nDA  - 2010\nVL  - 84\nSP  - 11336\nEP  - 49\nC1  - true\nIS  - 21\nLA  - \nER  - \n\nTY  - JOUR\nTI  - Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission\nT2  - Sci Rep\nPY  - 2018\nDA  - 2018\nVL  - 8\nSP  - 15177\nC1  - true\nT2  - Annex: Annex figure. Non-redundant alignments of SARS-related CoVs focused on oligonucleotide binding sites of all assays (top to bottom: RdRp, E, N). Viruses not present in these alignments have been removed because their binding sites are 100% identical to one of the members of the alignment. (\u201c--\u201c) means sequence gaps not covered by oligonucleotides. Note that these alignments contain only one sequence of 2019-nCoV while Figure 2 above contains all presently released sequences. We will fuse this into one figure\nIS  - 1\nLA  - \nER  - \n\nTY  - GEN\nTI  - First line screening assay\nLA  - \nER  - \n\nTY  - GEN\nTI  - Confirmatory assay\nLA  - \nER  - \n\nTY  - GEN\nTI  - Discrimatory assay\nLA  - \nER  - \n\n",
        "author_conclusions": [],
        "table_captions": [
            {
                "id": "1",
                "caption": "Primers and probes"
            },
            {
                "id": "2",
                "caption": "Cell-culture supernatants tested by all assays"
            },
            {
                "id": "3",
                "caption": "Tests of known respiratory viruses and bacteria in clinical samples"
            }
        ],
        "figure_captions": [
            {
                "id": "2",
                "caption": "Partial alignments of oligonucleotide binding regions. Panels show six available sequences of 2019-nCoV, aligned to the corresponding partial sequences of SARS-CoV strain Frankfurt 1, which can be used as a positive control for all three RT-PCR assays. The alignment also contains the most closely-related bat virus (Bat SARS-related CoV isolate bat-SL-CoVZC45, GenBank Acc.No MG772933.1) as well as the most distant member within the SARS-related bat CoV clade, detected in Bulgaria (GenBank Acc. No NC_014470). Dots represent identical nucleotides compared to sequence Wuhan-Hu 1. Substitutions are specified. More comprehensive alignments in the Appendix"
            },
            {
                "id": "3",
                "caption": "A, E-gene assay, B, RdRp gene assay. X-axis shows input RNA copies per reaction. Y-axis shows positive results in all parallel reactions performed, squares are experimental data points resulting from replicate testing of given concentrations (x-axis) in parallels assays (8 replicate reactions per datum point). The inner line is a probit curve (dose-response rule). The outer dotted lines are 95% confidence intervals"
            },
            {
                "id": "4",
                "caption": "Preliminary experiment comparing single probe assay for SARS-CoV (probe RdRP_SARSr-P1, left panel) with single probe assay for 2019-nCoV (probe RdRP_SARSrP2, right panel). Note that the fluorescent signal in these assays is suboptimal due to the use of PCR-generated targets"
            }
        ],
        "tables_url": "https://scholarcy.nyc3.digitaloceanspaces.com/tables/docker-test/ea.pl.xlsx",
        "figure_urls": [
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/ea.pl/img-002.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/ea.pl/img-003.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/ea.pl/img-005.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/ea.pl/img-006.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/ea.pl/img-008.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/ea.pl/img-010.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/ea.pl/img-012.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/ea.pl/img-013.png"
        ]
    },
    "sections": {
        "background": [
            "We used known SARS- and SARS-related coronaviruses (bat viruses from our own studies as well as literature sources) to generate a non-redundant alignment (excerpts shown in Annex). We designed candidate diagnostic RT-PCR assays before release of the first sequence of 2019-nCoV. Upon sequence release, the following assays were selected based on their matching to 2019-nCoV as per inspection of the sequence alignment and initial evaluation (Figures 1 and 2).<br/><br/>All assays can use SARS-CoV genomic RNA as positive control. Synthetic control RNA for 2019-nCoV E gene assay is available via EVAg. Synthetic control for 2019nCoV RdRp is expected to be available via EVAg from Jan 21st onward."
        ],
        "annex": [
            "Annex figure. Non-redundant alignments of SARS-related CoVs focused on oligonucleotide binding sites of all assays (top to bottom: RdRp, E, N). Viruses not present in these alignments have been removed because their binding sites are 100% identical to one of the members of the alignment. (\u201c--\u201c) means sequence gaps not covered by oligonucleotides. Note that these alignments contain only one sequence of 2019-nCoV while Figure 2 above contains all presently released sequences. We will fuse this into one figure.<br/><br/>Workflow Protocol"
        ]
    },
    "structured_content": {
        "Background": [
            "We used known SARS- and SARS-related coronaviruses (bat viruses from our own studies as well as literature sources) to generate a non-redundant alignment (excerpts shown in Annex). We designed candidate diagnostic RT-PCR assays before release of the first sequence of 2019-nCoV. Upon sequence release, the following assays were selected based on their matching to 2019-nCoV as per inspection of the sequence alignment and initial evaluation (Figures 1 and 2).",
            "All assays can use SARS-CoV genomic RNA as positive control. Synthetic control RNA for 2019-nCoV E gene assay is available via EVAg. Synthetic control for 2019nCoV RdRp is expected to be available via EVAg from Jan 21st onward.",
            "Figure 1 relative positions of amplicon targets on SARS-CoV an 2019-nCoV genome. ORF: open reading frame; RdRp: RNA-dependent RNA polymerase. Numbers below amplicon are genome positions according to SARS-CoV, NC_004718.",
            "Clinical samples and CoV cell culture supernatants Respiratory samples were obtained during 2019 from patients hospitalized at Charit\u00e9 medical center and tested by the NxTAG\u00ae Respiratory Pathogen Panel (Luminex) or in cases of MERS-CoV by the MERS-CoV upE assay as published before (1).",
            "Cell culture supernatants from typed coronaviruses were available at our research and clinical laboratories. The typed avian influenza virus RNA (H5N1) was obtained from the German Society for Promotion of Quality Assurance in Medical Laboratories (INSTAND) proficiency testing panels. RNA was extracted from clinical samples by using the MagNA Pure 96 system (Roche) and from cell culture supernatants by the viral RNA mini kit (Qiagen).",
            "Assay design For oligonucleotide design and in-silico evaluation we downloaded all complete and partial (if >400 nucleotides) SARS-related virus sequences available at GenBank by January 1st, 2020. The list (n=729 entries) was manually checked and artificial sequences (lab-derived, synthetic etc.), as well as sequence duplicates removed, resulting in a final list of 375",
            "sequences. These sequences were aligned and the alignment used for assay design. The alignment was later complemented by sequences released from the Wuhan cluster. All presently release sequences match the amplicons (Figure 2). An overview of oligonucleotide binding sites in all unique sequences of bat-associated SARS-related viruses is shown in the appendix.",
            "Real-time reverse-transcription polymerase chain reaction All assays used the same conditions. Primer and probe sequences, as well as optimized concentrations are shown in Table 1. A 25-\u03bcl reaction was set up containing 5 \u03bcl of RNA, 12.5 \u03bcl of 2 X reaction buffer provided with the Superscript III one step RT-PCR system with Platinum Taq Polymerase (Invitrogen; containing 0.4 mM of each deoxyribonucleotide triphosphates (dNTP) and 3.2 mM magnesium sulfate), 1 \u03bcl of reverse transcriptase/Taq mixture from the kit, 0.4 \u03bcl of a 50 mM magnesium sulfate solution (Invitrogen \u2013 not provided with the kit), and 1 \u03bcg of nonacetylated bovine serum albumin (Roche). All oligonucleotides were synthesised and provided by Tib-Molbiol, Berlin. Thermal cycling was performed at 55\u00b0C for 10 min for reverse transcription, followed by 95\u00b0C for 3 min and then 45 cycles of 95\u00b0C for 15 s, 58\u00b0C for 30 s.",
            "Optimized concentrations are mol per liter of final reaction mix.",
            "(e.g., 1.5 microliters of a 10 micromolar (uM) primer stock solution per 25 microliter (ul) total reaction volume yields a final concentration of 600 nanomol per liter (nM) as indicated in the table) -note that standard, non-optimized reaction conditions as indicated by suppliers of one-step RT-PCR kits will generally yield sufficient sensitivity-",
            "Specific for 2019-nCoV, will not detect SARSCoV use 100 nM per reaction and mix with P1",
            "Pan Sarbeco-Probe, will detect 2019-nCoV, SARS-CoV and bat-SARS-related CoVs use 100 nM per reaction and mix with P2 use 400 nM per reaction use 400 nM per reaction use 200 nM per reaction",
            "W is A/T; R is G/A; M is A/C ; FAM, 6-carboxyfluorescein; BBQ, blackberry quencher",
            "Technical sensitivity testing Preliminary assessment of analytical sensitivity for RdRp assay.",
            "We tested purified cell culture supernatant containing SARS-CoV strain Frankfurt-1 virions grown on Vero cells, and quantified by real-time RT-PCR assay as described in Drosten et al (2) using a specific in-vitro transcribed RNA quantification standard. The results are shown in Figure 3. All assays are highly sensitive.",
            "A A. First line assay: E gene Technical limit of detection (LOD) = 5.2 RNA copies/reaction, at 95% hit rate; 95% CI: 3.7-9.6 RNA copies/reaction.",
            "B. Confirmatory assay: RdRP gene Technical LOD = 3.8 RNA copies/reaction, at 95% hit rate; 95% CI: 2.7-7.6 RNA copies/reaction.",
            "RdRp assay sensitivity with single probe application using the assay variant that only contains the 2019-nCoV specific probe.",
            "To show that the assays will detect other bat-associated SARS-related viruses, we tested bat-derived fecal samples available from Drexler et al, (3) und Muth et al, (4) using the novel assays.",
            "KC633203, Betacoronavirus BtCoV/Rhi_eur/BB98-98/BGR/2008 KC633204, Betacoronavirus BtCoV/Rhi_eur/BB98-92/BGR/2008 KC633201, Betacoronavirus BtCoV/Rhi_bla/BB98-22/BGR/2008 GU190221 Betacoronavirus Bat coronavirus BR98-19/BGR/2008 GU190222 Betacoronavirus Bat coronavirus BM98-01/BGR/2008 GU190223, Betacoronavirus Bat coronavirus BM98-13/BGR/2008",
            "All samples were successfully tested positive by the E gene assay. Detection of these relatively distant members of the SARS-related CoV clade suggests that all Asian viruses are likely to be detected.",
            "1. Chemical stability To exclude non-specific reactivity of oligonucleotides among each other, both assays were tested 40 times in parallel with water and no other nucleic acid except the provided oligonucleotides. In none of these reactions was any positive signal detected.",
            "2. Cross-reactivity with other coronaviruses Cell culture supernatants containing human coronaviruses (HCoV)-229E, -NL63, -OC43, and -HKU1 as well as MERS-CoV were tested in all three assays (Table 2). For the noncultivable HCoV-HKU1, supernatant from human airway culture was used. Virus RNA concentration in all samples was determined by specific real-time RT-PCRs and in-vitro transcribed RNA standards designed for absolute viral load quantification.",
            "3. Tests of human clinical samples previously tested to contain respiratory viruses Both assays were applied on human clinical samples from our own diagnostic services, previously tested positive for the viruses listed in Table 3. All tests returned negative results.",
            "HCoV-HKU1 HCoV-OC43 HCoV-NL63 HCoV-229E MERS-CoV Influenza A (H1N1/09) Influenza A (H3N2) Influenza A(H5N1)"
        ],
        "References": [
            "1. Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill. 2012;17(39). 2. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967-76. 3. Drexler JF, Gloza-Rausch F, Glende J, Corman VM, Muth D, Goettsche M, et al Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol. 2010;84(21):11336-49. 4. Muth D, Corman VM, Roth H, Binger T, Dijkman R, Gottula LT, et al Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission. Sci Rep. 2018;8(1):15177.",
            "Annex: Annex figure. Non-redundant alignments of SARS-related CoVs focused on oligonucleotide binding sites of all assays (top to bottom: RdRp, E, N). Viruses not present in these alignments have been removed because their binding sites are 100% identical to one of the members of the alignment. (\u201c--\u201c) means sequence gaps not covered by oligonucleotides. Note that these alignments contain only one sequence of 2019-nCoV while Figure 2 above contains all presently released sequences. We will fuse this into one figure.",
            "Workflow Protocol"
        ],
        "1. First line screening assay": [
            "E assay: MasterMix: H2O (RNAse free) 2x Reaction mix* MgSO4(50mM) BSA (1 mg/ml)** Primer E_Sarbeco_F1 (10 \u03bcM stock solution) Primer E_Sarbeco_R2 (10 \u03bcM stock solution) Probe E_Sarbeco_P1 (10 \u03bcM stock solution) SSIII/Taq EnzymeMix* Total reaction mix Template RNA, add Total volume",
            "If assay No 1 is positive, continue to assay No 2."
        ],
        "2. Confirmatory assay": [
            "RdRp assay: MasterMix: H2O (RNAse free) 2x Reaction mix* MgSO4(50mM) BSA (1 mg/ml)** Primer RdRP_SARSr-F2 (10 \u03bcM stock solution) Primer RdRP_SARSr-R1 (10 \u03bcM stock solution) Probe RdRP_SARSr-P1 (10 \u03bcM stock solution) Probe RdRP_SARSr-P2 (10 \u03bcM stock solution) SSIII/Taq EnzymeMix* Total reaction mix Template RNA, add Total volume",
            "If assay No 2 is positive, continue to assay No 3."
        ],
        "3. Discrimatory assay": [
            "MasterMix: H2O (RNAse free) 2x Reaction mix* MgSO4(50mM) BSA (1 mg/ml)** Primer RdRP_SARSr-F2 (10 \u03bcM stock solution) Primer RdRP_SARSr-R1 (10 \u03bcM stock solution) Probe RdRP_SARSr-P2 (10 \u03bcM stock solution) SSIII/Taq EnzymeMix* Total reaction mix Template RNA, add Total volume",
            "GTGARATGGTCATGTGTGGCGG CARATGTTAAASACACTATTAGCATA FAM-CAGGTGGAACCTCATCAGGAGATGC-BBQ",
            "Note: Other generic real-time RT-PCR reagents can be used for all assays. In this case, use oligonucleotides at concentrations indicated. If using Light Cycler instrument with glass capillaries, use Light Cycler-specific reagents or add BSA as indicated in the detailed documentation above."
        ]
    },
    "participants": [
        {
            "participant": "data",
            "number": 729,
            "context": "Assay design For oligonucleotide design and in-silico evaluation we downloaded all complete and partial (if >400 nucleotides) SARS-related virus sequences available at GenBank by January 1st, 2020. <mark class=\"stats\">The list (n=729 entries) was manually checked and artificial sequences (lab-derived, synthetic etc.), as well as sequence duplicates removed, resulting in a final list of 375</mark>. sequences"
        }
    ],
    "statistics": [],
    "keywords": [
        "initial evaluation",
        "synthetic control",
        "literature source",
        "severe acute respiratory syndrome",
        "non redundant",
        "cov genomic",
        "human coronaviruses",
        "bat virus",
        "coronavirus",
        "SARS",
        "nanomol per liter",
        "candidate diagnostic",
        "pcr assay",
        "rt pcr",
        "positive control",
        "redundant alignment",
        "Viral disease",
        "genomic rna",
        "limit of detection",
        "novel coronavirus",
        "sars cov",
        "deoxyribonucleotide triphosphates",
        "control rna",
        "ncov e",
        "diagnostic rt",
        "sequence alignment",
        "sequence release"
    ],
    "keyword_relevance": {
        "SARS": 0.36082474226804123,
        "coronavirus": 0.26804123711340205,
        "nanomol per liter": 0.09278350515463918,
        "human coronaviruses": 0.08247422680412371,
        "limit of detection": 0.030927835051546393,
        "severe acute respiratory syndrome": 0.020618556701030927,
        "bat virus": 0.020618556701030927,
        "positive control": 0.020618556701030927,
        "redundant alignment": 0.020618556701030927,
        "deoxyribonucleotide triphosphates": 0.020618556701030927,
        "initial evaluation": 0.010309278350515464,
        "literature source": 0.010309278350515464,
        "candidate diagnostic": 0.010309278350515464,
        "novel coronavirus": 0.010309278350515464,
        "sequence alignment": 0.010309278350515464,
        "sequence release": 0.010309278350515464,
        "synthetic control": 0.0,
        "non redundant": 0.0,
        "cov genomic": 0.0,
        "pcr assay": 0.0,
        "rt pcr": 0.0,
        "Viral disease": 0.0,
        "genomic rna": 0.0,
        "sars cov": 0.0,
        "control rna": 0.0,
        "ncov e": 0.0,
        "diagnostic rt": 0.0
    },
    "species": [],
    "summary": [
        "The authors used known SARS- and SARS-related coronaviruses to generate a non-redundant alignment.",
        "The authors designed candidate diagnostic RT-PCR assays before release of the first sequence of 2019-nCoV.",
        "All assays can use SARS-CoV genomic RNA as positive control.",
        "Figure 1 relative positions of amplicon targets on SARS-CoV an 2019-nCoV genome.",
        "Clinical samples and CoV cell culture supernatants Respiratory samples were obtained during 2019 from patients hospitalized at Charit\u00e9 medical center and tested by the NxTAG\u00ae Respiratory Pathogen Panel (Luminex) or in cases of MERS-CoV by the MERS-CoV upE assay as published before (1).",
        "Assay design For oligonucleotide design and in-silico evaluation the authors downloaded all complete and partial SARS-related virus sequences available at GenBank by January 1st, 2020.",
        "An overview of oligonucleotide binding sites in all unique sequences of bat-associated SARS-related viruses is shown in the appendix.",
        "(e.g., 1.5 microliters of a 10 micromolar primer stock solution per 25 microliter total reaction volume yields a final concentration of 600 nanomol per liter as indicated in the table) -note that standard, non-optimized reaction conditions as indicated by suppliers of one-step RT-PCR kits will generally yield sufficient sensitivity-",
        "Assay/ Use RdRP gene",
        "Specific for 2019-nCoV, will not detect SARSCoV use 100 nM per reaction and mix with P1",
        "The authors tested purified cell culture supernatant containing SARS-CoV strain Frankfurt-1 virions grown on Vero cells, and quantified by real-time RT-PCR assay as described in Drosten et al (2) using a specific in-vitro transcribed RNA quantification standard.",
        "First line assay: E gene Technical limit of detection (LOD) = 5.2 RNA copies/reaction, at 95% hit rate; 95% CI: 3.7-9.6 RNA copies/reaction.",
        "B. Confirmatory assay: RdRP gene Technical LOD = 3.8 RNA copies/reaction, at 95% hit rate; 95% CI: 2.7-7.6 RNA copies/reaction.",
        "To show that the assays will detect other bat-associated SARS-related viruses, the authors tested bat-derived fecal samples available from Drexler et al, (3) und Muth et al, (4) using the novel assays.",
        "All samples were successfully tested positive by the E gene assay.",
        "2. Cross-reactivity with other coronaviruses Cell culture supernatants containing human coronaviruses (HCoV)-229E, -NL63, -OC43, and -HKU1 as well as MERS-CoV were tested in all three assays (Table 2).",
        "Virus RNA concentration in all samples was determined by specific real-time RT-PCRs and in-vitro transcribed RNA standards designed for absolute viral load quantification.",
        "3. Tests of human clinical samples previously tested to contain respiratory viruses Both assays were applied on human clinical samples from the own diagnostic services, previously tested positive for the viruses listed in Table 3."
    ],
    "structured_summary": {
        "Introduction": [
            "The authors used known SARS- and SARS-related coronaviruses to generate a non-redundant alignment.",
            "The authors designed candidate diagnostic RT-PCR assays before release of the first sequence of 2019-nCoV.",
            "All assays can use SARS-CoV genomic RNA as positive control.",
            "Figure 1 relative positions of amplicon targets on SARS-CoV an 2019-nCoV genome."
        ],
        "Results": [
            "Clinical samples and CoV cell culture supernatants Respiratory samples were obtained during 2019 from patients hospitalized at Charit\u00e9 medical center and tested by the NxTAG\u00ae Respiratory Pathogen Panel (Luminex) or in cases of MERS-CoV by the MERS-CoV upE assay as published before (1).",
            "Assay design For oligonucleotide design and in-silico evaluation the authors downloaded all complete and partial SARS-related virus sequences available at GenBank by January 1st, 2020.",
            "An overview of oligonucleotide binding sites in all unique sequences of bat-associated SARS-related viruses is shown in the appendix.",
            "(e.g., 1.5 microliters of a 10 micromolar primer stock solution per 25 microliter total reaction volume yields a final concentration of 600 nanomol per liter as indicated in the table) -note that standard, non-optimized reaction conditions as indicated by suppliers of one-step RT-PCR kits will generally yield sufficient sensitivity-",
            "Assay/ Use RdRP gene",
            "Specific for 2019-nCoV, will not detect SARSCoV use 100 nM per reaction and mix with P1",
            "The authors tested purified cell culture supernatant containing SARS-CoV strain Frankfurt-1 virions grown on Vero cells, and quantified by real-time RT-PCR assay as described in Drosten et al (2) using a specific in-vitro transcribed RNA quantification standard.",
            "First line assay: E gene Technical limit of detection (LOD) = 5.2 RNA copies/reaction, at 95% hit rate; 95% CI: 3.7-9.6 RNA copies/reaction.",
            "B. Confirmatory assay: RdRP gene Technical LOD = 3.8 RNA copies/reaction, at 95% hit rate; 95% CI: 2.7-7.6 RNA copies/reaction.",
            "To show that the assays will detect other bat-associated SARS-related viruses, the authors tested bat-derived fecal samples available from Drexler et al, (3) und Muth et al, (4) using the novel assays."
        ],
        "Conclusion": [
            "All samples were successfully tested positive by the E gene assay.",
            "2. Cross-reactivity with other coronaviruses Cell culture supernatants containing human coronaviruses (HCoV)-229E, -NL63, -OC43, and -HKU1 as well as MERS-CoV were tested in all three assays (Table 2).",
            "Virus RNA concentration in all samples was determined by specific real-time RT-PCRs and in-vitro transcribed RNA standards designed for absolute viral load quantification.",
            "3. Tests of human clinical samples previously tested to contain respiratory viruses Both assays were applied on human clinical samples from the own diagnostic services, previously tested positive for the viruses listed in Table 3."
        ]
    },
    "reference_links": [
        {
            "id": "1",
            "alt_id": "Corman_et+al_2012_a",
            "entry": "1. Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill. 2012;17(39).",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Corman%2C%20V.M.%20Eckerle%2C%20I.%20Bleicker%2C%20T.%20Zaki%2C%20A.%20Detection%20of%20a%20novel%20human%20coronavirus%20by%20real-time%20reverse-transcription%20polymerase%20chain%20reaction%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Corman%2C%20V.M.%20Eckerle%2C%20I.%20Bleicker%2C%20T.%20Zaki%2C%20A.%20Detection%20of%20a%20novel%20human%20coronavirus%20by%20real-time%20reverse-transcription%20polymerase%20chain%20reaction%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Corman%2C%20V.M.%20Eckerle%2C%20I.%20Bleicker%2C%20T.%20Zaki%2C%20A.%20Detection%20of%20a%20novel%20human%20coronavirus%20by%20real-time%20reverse-transcription%20polymerase%20chain%20reaction%202012"
        },
        {
            "id": "2",
            "alt_id": "Drosten_et+al_2003_a",
            "entry": "2. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967-76.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Drosten%2C%20C.%20Gunther%2C%20S.%20Preiser%2C%20W.%20van%20der%20Werf%2C%20S.%20Identification%20of%20a%20novel%20coronavirus%20in%20patients%20with%20severe%20acute%20respiratory%20syndrome%202003",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Drosten%2C%20C.%20Gunther%2C%20S.%20Preiser%2C%20W.%20van%20der%20Werf%2C%20S.%20Identification%20of%20a%20novel%20coronavirus%20in%20patients%20with%20severe%20acute%20respiratory%20syndrome%202003",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Drosten%2C%20C.%20Gunther%2C%20S.%20Preiser%2C%20W.%20van%20der%20Werf%2C%20S.%20Identification%20of%20a%20novel%20coronavirus%20in%20patients%20with%20severe%20acute%20respiratory%20syndrome%202003"
        },
        {
            "id": "3",
            "alt_id": "Drexler_et+al_2010_a",
            "entry": "3. Drexler JF, Gloza-Rausch F, Glende J, Corman VM, Muth D, Goettsche M, et al. Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences. J Virol. 2010;84(21):11336-49.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Drexler%2C%20J.F.%20Gloza-Rausch%2C%20F.%20Glende%2C%20J.%20Corman%2C%20V.M.%20Genomic%20characterization%20of%20severe%20acute%20respiratory%20syndrome-related%20coronavirus%20in%20European%20bats%20and%20classification%20of%20coronaviruses%20based%20on%20partial%20RNA-dependent%20RNA%20polymerase%20gene%20sequences%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Drexler%2C%20J.F.%20Gloza-Rausch%2C%20F.%20Glende%2C%20J.%20Corman%2C%20V.M.%20Genomic%20characterization%20of%20severe%20acute%20respiratory%20syndrome-related%20coronavirus%20in%20European%20bats%20and%20classification%20of%20coronaviruses%20based%20on%20partial%20RNA-dependent%20RNA%20polymerase%20gene%20sequences%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Drexler%2C%20J.F.%20Gloza-Rausch%2C%20F.%20Glende%2C%20J.%20Corman%2C%20V.M.%20Genomic%20characterization%20of%20severe%20acute%20respiratory%20syndrome-related%20coronavirus%20in%20European%20bats%20and%20classification%20of%20coronaviruses%20based%20on%20partial%20RNA-dependent%20RNA%20polymerase%20gene%20sequences%202010"
        },
        {
            "id": "4",
            "alt_id": "Muth_2018_a",
            "entry": "4. Muth D, Corman VM, Roth H, Binger T, Dijkman R, Gottula LT, et al. Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission. Sci Rep. 2018;8(1):15177. Annex: Annex figure. Non-redundant alignments of SARS-related CoVs focused on oligonucleotide binding sites of all assays (top to bottom: RdRp, E, N). Viruses not present in these alignments have been removed because their binding sites are 100% identical to one of the members of the alignment. (\u201c--\u201c) means sequence gaps not covered by oligonucleotides. Note that these alignments contain only one sequence of 2019-nCoV while Figure 2 above contains all presently released sequences. We will fuse this into one figure.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Muth%20D%20Corman%20VM%20Roth%20H%20Binger%20T%20Dijkman%20R%20Gottula%20LT%20et%20al%20Attenuation%20of%20replication%20by%20a%2029%20nucleotide%20deletion%20in%20SARScoronavirus%20acquired%20during%20the%20early%20stages%20of%20humantohuman%20transmission%20Sci%20Rep%2020188115177%20Annex%20Annex%20figure%20Nonredundant%20alignments%20of%20SARSrelated%20CoVs%20focused%20on%20oligonucleotide%20binding%20sites%20of%20all%20assays%20top%20to%20bottom%20RdRp%20E%20N%20Viruses%20not%20present%20in%20these%20alignments%20have%20been%20removed%20because%20their%20binding%20sites%20are%20100%20identical%20to%20one%20of%20the%20members%20of%20the%20alignment%20%20means%20sequence%20gaps%20not%20covered%20by%20oligonucleotides%20Note%20that%20these%20alignments%20contain%20only%20one%20sequence%20of%202019nCoV%20while%20Figure%202%20above%20contains%20all%20presently%20released%20sequences%20We%20will%20fuse%20this%20into%20one%20figure",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Muth%20D%20Corman%20VM%20Roth%20H%20Binger%20T%20Dijkman%20R%20Gottula%20LT%20et%20al%20Attenuation%20of%20replication%20by%20a%2029%20nucleotide%20deletion%20in%20SARScoronavirus%20acquired%20during%20the%20early%20stages%20of%20humantohuman%20transmission%20Sci%20Rep%2020188115177%20Annex%20Annex%20figure%20Nonredundant%20alignments%20of%20SARSrelated%20CoVs%20focused%20on%20oligonucleotide%20binding%20sites%20of%20all%20assays%20top%20to%20bottom%20RdRp%20E%20N%20Viruses%20not%20present%20in%20these%20alignments%20have%20been%20removed%20because%20their%20binding%20sites%20are%20100%20identical%20to%20one%20of%20the%20members%20of%20the%20alignment%20%20means%20sequence%20gaps%20not%20covered%20by%20oligonucleotides%20Note%20that%20these%20alignments%20contain%20only%20one%20sequence%20of%202019nCoV%20while%20Figure%202%20above%20contains%20all%20presently%20released%20sequences%20We%20will%20fuse%20this%20into%20one%20figure",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Muth%20D%20Corman%20VM%20Roth%20H%20Binger%20T%20Dijkman%20R%20Gottula%20LT%20et%20al%20Attenuation%20of%20replication%20by%20a%2029%20nucleotide%20deletion%20in%20SARScoronavirus%20acquired%20during%20the%20early%20stages%20of%20humantohuman%20transmission%20Sci%20Rep%2020188115177%20Annex%20Annex%20figure%20Nonredundant%20alignments%20of%20SARSrelated%20CoVs%20focused%20on%20oligonucleotide%20binding%20sites%20of%20all%20assays%20top%20to%20bottom%20RdRp%20E%20N%20Viruses%20not%20present%20in%20these%20alignments%20have%20been%20removed%20because%20their%20binding%20sites%20are%20100%20identical%20to%20one%20of%20the%20members%20of%20the%20alignment%20%20means%20sequence%20gaps%20not%20covered%20by%20oligonucleotides%20Note%20that%20these%20alignments%20contain%20only%20one%20sequence%20of%202019nCoV%20while%20Figure%202%20above%20contains%20all%20presently%20released%20sequences%20We%20will%20fuse%20this%20into%20one%20figure"
        },
        {
            "id": "1",
            "alt_id": "1._0000_a",
            "entry": "1. First line screening assay",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=First%20line%20screening%20assay"
        },
        {
            "id": "2",
            "alt_id": "2._0000_b",
            "entry": "2. Confirmatory assay",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Confirmatory%20assay"
        },
        {
            "id": "3",
            "alt_id": "3._0000_c",
            "entry": "3. Discrimatory assay ",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Discrimatory%20assay"
        }
    ],
    "facts": [
        "the following assays were selected based on their matching",
        "Synthetic control RNA for 2019-nCoV E gene assay is available via EVAg",
        "Synthetic control for 2019nCoV RdRp is expected to be available via EVAg from Jan 21st",
        "from patients hospitalized at Charit\u00e9 medical center",
        "An overview of oligonucleotide binding sites in all unique sequences of bat-associated SARS-related viruses is shown in the appendix",
        "tested purified cell culture supernatant containing SARS-CoV strain Frankfurt-1 virions grown on Vero cells",
        "by real-time RT-PCR assay as described in Drosten et al using a specific",
        "All samples were successfully tested positive by the E gene assay",
        "well as MERS-CoV were tested in all three assays",
        "Virus RNA concentration in all samples was determined by specific real-time RT-PCRs",
        "in-vitro transcribed RNA standards designed for absolute viral load quantification",
        "contain respiratory viruses Both assays were applied on human clinical samples from our own diagnostic services",
        "positive for the viruses listed in Table 3"
    ],
    "claims": [],
    "findings": [
        "First line assay: E gene Technical limit of detection (LOD) = 5.2 RNA copies/reaction, at 95% hit rate; 95% CI: 3.7-9.6 RNA copies/reaction",
        "Confirmatory assay: RdRP gene Technical LOD = 3.8 RNA copies/reaction, at 95% hit rate; 95% CI: 2.7-7.6 RNA copies/reaction"
    ],
    "processes": [],
    "key_statements": [
        "The following assays were selected based on their matching to 2019-nCoV as per inspection of the sequence alignment and initial evaluation (Figures 1 and 2)",
        "Synthetic control RNA for 2019-nCoV E gene assay is available via EVAg",
        "Synthetic control for 2019nCoV RdRp is expected to be available via EVAg from Jan 21st onward",
        "We tested purified cell culture supernatant containing SARS-CoV strain Frankfurt-1 virions grown on Vero cells, and quantified by real-time RT-PCR assay as described in Drosten et al (2) using a specific in-vitro transcribed RNA quantification standard",
        "First line assay: E gene Technical limit of detection (LOD) = 5.2 RNA copies/reaction, at 95% hit rate; 95% CI: 3.7-9.6 RNA copies/reaction",
        "Cross-reactivity with other coronaviruses Cell culture supernatants containing human coronaviruses (HCoV)-229E, -NL63, -OC43, and -HKU1 as well as MERS-CoV were tested in all three assays (Table 2)",
        "Virus RNA concentration in all samples was determined by specific real-time RT-PCRs and in-vitro transcribed RNA standards designed for absolute viral load quantification"
    ],
    "top_statements": [
        "We used known SARS- and SARS-related coronaviruses to generate a non-redundant alignment",
        "The following assays were selected based on their matching to 2019-nCoV as per inspection of the sequence alignment and initial evaluation (Figures 1 and 2)",
        "Synthetic control RNA for 2019-nCoV E gene assay is available via EVAg",
        "Synthetic control for 2019nCoV RdRp is expected to be available via EVAg from Jan 21st onward",
        "We tested purified cell culture supernatant containing SARS-CoV strain Frankfurt-1 virions grown on Vero cells, and quantified by real-time RT-PCR assay as described in Drosten et al (2) using a specific in-vitro transcribed RNA quantification standard",
        "First line assay: E gene Technical limit of detection (LOD) = 5.2 RNA copies/reaction, at 95% hit rate; 95% CI: 3.7-9.6 RNA copies/reaction",
        "Cross-reactivity with other coronaviruses Cell culture supernatants containing human coronaviruses (HCoV)-229E, -NL63, -OC43, and -HKU1 as well as MERS-CoV were tested in all three assays (Table 2)"
    ],
    "headline": "The following assays were selected based on their matching to 2019-nCoV as per inspection of the sequence alignment and initial evaluation",
    "contexts": [],
    "abbreviations": {
        "dNTP": "deoxyribonucleotide triphosphates",
        "nM": "nanomol per liter",
        "LOD": "limit of detection",
        "HCoV": "human coronaviruses"
    }
}
